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Abstract: Single cell genomics and proteomics with the combination of innovative three-dimensional
(3D) cell culture techniques can open new avenues toward the understanding of intra-tumor
heterogeneity. Here, we characterize lung cancer markers using single cell mass cytometry to
compare different in vitro cell culturing methods: two-dimensional (2D), carrier-free, or bead-based
3D culturing with in vivo xenografts. Proliferation, viability, and cell cycle phase distribution has
been investigated. Gene expression analysis enabled the selection of markers that were overexpressed:
TMEM45A, SLC16A3, CD66, SLC2A1, CA9, CD24, or repressed: EGFR either in vivo or in long-term
3D cultures. Additionally, TRA-1-60, pan-keratins, CD326, Galectin-3, and CD274, markers with
known clinical significance have been investigated at single cell resolution. The described twelve
markers convincingly highlighted a unique pattern reflecting intra-tumor heterogeneity of 3D samples
and in vivo A549 lung cancer cells. In 3D systems CA9, CD24, and EGFR showed higher expression
than in vivo. Multidimensional single cell proteome profiling revealed that 3D cultures represent a
transition from 2D to in vivo conditions by intermediate marker expression of TRA-1-60, TMEM45A,
pan-keratin, CD326, MCT4, Gal-3, CD66, GLUT1, and CD274. Therefore, 3D cultures of NSCLC cells
bearing more putative cancer targets should be used in drug screening as the preferred technique
rather than the Petri-dish.
Keywords: single cell mass cytometry; single cell proteomics; non-small cell lung cancer;
three-dimensional tissue culture
1. Introduction
Development of single-cell analytical techniques extends our understanding of cell population
heterogeneity and enables the identification and characterization of highly specialized rare cell
types [1]. Single cell genomics (e.g., single cell RNAseq) and single cell proteomics (e.g., mass
cytometry) have revolutionized our knowledge about the co-ordination of different cell types in tissue
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microenvironments unveiling their characteristic protein patterns [2,3]. Although image-based single
cell analysis has also been developed [4], single cell mass cytometry has been adopted to investigate
millions of cells per sample and it offers multi-dimensional data analysis with the characterization of
multiple proteins at single cell resolution [5].
Lung cancer accounts for the majority, 25% of all cancer-related deaths worldwide and the 5-years
overall survival at 17.7% has achieved very little progress in the last decades [6]. Adenocarcinomas
account for the majority, 40% of all lung cancer histological types [7]. Here, we focus on the
mass cytometric single cell analysis of a non-small cell lung carcinoma (NSCLC) model, the A549
adenocarcinoma cells. The heterogeneity of immune subsets infiltrating non-small cell lung cancer
has been previously published based on mass cytometric profiling [8]. Here, we focus on marker
expression of lung cancer cells obtained from different culture conditions at single cell resolution.
Organoid cell culturing revolutionized cell biology since in vitro three-dimensional (3D)
multicellular spheroid models mimic better the physiology of complex tissues compared to conventional
two-dimensional (2D) monolayer cultures [9]. For a more successful treatment of lung cancer, a better
understanding of cancer development in the tissue microenvironment and further improvements
in in vitro experimental techniques are needed [10]. Ideal models systems, for screening of novel
drug candidates should mimic the molecular, functional and histopathological complexity of in vivo
tumors more accurately. Although multi-cellular tumor spheroid models were introduced in the
early 1970s [11,12], their implementation in the pre-clinical phase of drug development was neglected
resulting in numerous failed clinical trials [13].
Currently, there is a wide variety of techniques for three-dimensional cell culture methods:
specially designed incubators, tubes, microcarriers and growing matrices [13]. Various extracellular
matrix (ECM) components and their homologues (collagen, gelatin, etc.) are used to facilitate the
adhesion of cells to the carriers [14,15]. Investigation of tumor spheroids revealed, that the core of
the spheroid was similar to in vivo conditions. Three-dimensional spheroids mimic the organoid
of a solid tumor, while 2D culture methods fail to represent different tissue areas within tumors,
such as proliferating, quiescent and necrotic core zones [16]. So far, the traditional in vitro screening
of drug candidates in cell-based assays has been based on adherent cultures (2D assays) [17,18],
but several studies reported the application of cancer multicellular spheroids for screening and target
identification [14,19–22]. It has been shown by us [23,24] and others [25,26] that the cells grown
on 2D surfaces demonstrate higher drug sensitivity. The monolayer culture of the human breast
cancer cell line MCF-7 showed 2.6-fold higher accumulation of doxorubicin, paclitaxel, and tamoxifen
compared to three-dimensional cultivation on porous biodegradable polymeric microparticles [27].
Only 26% of cells in 3D reached the same concentration of drugs as the cells treated in 2D dishes
because the synthesis of ECM components was more intense in 3D cultures [27]. Furthermore, cells in
monolayer culture not only have higher sensitivity to anticancer drugs upon treatment but they become
quiescent and decrease proliferation rate and increase apoptosis more quickly than 3D models or
in vivo tumors [10,13].
In this study, we characterized 2D, 3D and in vivo models by a state-of-the-art single cell mass
cytometry technique. Here, we show that A549 lung cancer cells grown by organic scaffolded or
scaffold-free 3D culturing methods represent the gene and protein expression patterns of in vivo
tumors better than standard 2D cultures.
2. Materials and Methods
2.1. Two-Dimensional (2D) Cell Culture
The NSCLC cell line A549 was purchased from the ATCC collection. Since cells were maintained in
our laboratory, cell identification of A549 cells was performed by Microsynth AG (Balgach, Switzerland).
Cells were maintained in DMEM/F12 (DMEM, PANTM Biotech; F12 Nut mix, Gibco, Thermo Fisher
Scientific, Waltham, MA, USA) containing 4.5 g/L glucose, 10% fetal bovine serum (FBS, Gibco),
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1X GlutaMAX (Gibco) 1% PenStrep antibiotics (Penicillin G sodium salt, and Streptomycin sulfate
salt, Sigma-Aldrich, St. Louis, MI, USA). The cells were cultured in standard tissue culture Petri-dish
(2D monolayer, 10 mm diameter dish, Corning Life Sciences, Corning, NY, USA); T-75 flasks (2D TC,
tissue culture flasks T75 flask, TPP, Trasadingen, Switzerland) or collagen type I covered T-75 flasks
(2D Coll, tissue culture flasks T75 flask, TPP) for time points day 4 and 9 at maximum 80% confluence
at standard atmosphere of 95% air and 5% CO2 (Sanyo, Osaka, Japan). At about 80% confluence cells
were washed, harvested with trypsin (Sigma-Aldrich) and seeded into new dish.
2.2. T-75 Flask Surface Coating
The collagen type I covered T-75 (2D Coll, tissue culture flasks T75 flask, TPP) flasks were coated
by 4 mL of 0.1% collagen (Collagen Type I, Sigma-Aldrich) diluted in sterile phosphate-buffered saline
(PBS, Sigma-Aldrich) at room temperature. After 30 min, the flasks were washed with sterile water
and dried under sterile hood before use.
2.3. Three-Dimensional Microcarrier Coating
Two types of microcarriers were used for 3D culturing. The Cytodex 3 (Sigma-Aldrich, 3D
Cytodex3) dextran microcarriers were purchased as prefabricated and precoated with denatured
porcine-skin collagen. The other type of microcarrier, Nutrisphere (Hamilton, Reno, NV, USA)
was coated by collagen (collagen type I, Sigma-Aldrich) in our laboratory (3D Nutrisphere).
2 mL of Nutrisphere magnetic microcarriers were transferred into silanized vials (Sigma-Aldrich)
and washed with sterile water and MOPS buffer solution (0.1M MOPS, pH 5.0, Sigma-Aldrich).
The activation of microcarriers was performed with EDC/NHS reagent: 600 mM EDC
(1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, Sigma-Aldrich) and 200 mM
NHS (N-hydroxysulfosuccinimide, Sigma-Aldrich) dissolved in 0.1 M MOPS buffer, pH 5.0
(Sigma-Aldrich). After 20 min surface activation at room temperature the microcarriers were washed
with phosphate-buffered saline at neutral pH. The coating was carried out on a shaker with slowly
agitation in 1 mL of 5 mg/mL collagen type I solution and incubated overnight under shaking condition
at room temperature. The next day, the supernatant was discarded, and the collagen-coated microbeads
were washed twice and finally resuspended in PBS, sterilized by autoclave (121 ◦C for 15 min) and
stored at 4 ◦C. Cells were grown on microcarriers at equivalent surface/volume ratio to T75 flasks.
2.4. Three-Dimensional (3D) Cell Culturing Using Bench-top Incubator System
A549 cells (3D Cytodex3, 3D Nutrisphere, and carrier-free spheroids) were cultured in specially
designed LeviTubes in the bench top bioreactor-incubator hybrid (BioLevitatorTM, Hamilton).
Cells were grown on microcarriers at equivalent surface/volume ratio to T75 flask. Cytodex3 beads
are 175 µm in diameter and surface varies between 200–230 cm2/mL. Nutrisphere beads are 65 µm in
diameter and surface is around 125 cm2/mL. To keep surface/volume ratio equivalent with the 75 cm2
of flask, 350 µL Cytodex3 and 602 µL Nutrisphere were used for inoculation, separately. Both for
microcarriers and carrier-free spheroids 1 × 106 cells were inoculated. During the cultivation, cells were
grown in suspension culture with or without microcarriers with the following setup: Inoculation
period was for 5 h: Rotation Pause: 0 s, Rotation Period: 1 s, Agitation Pause: 20 min, Rotation Speed:
50 rpm, Agitation Period: 5 min. Duration: 5 h. Culture period (protocol) was the following for 4 or
9 days: Rotation Pause 0 s, Rotation Period: 1 s, Rotation Speed: 75 rpm. Duration: ∞. LeviTubes
were filled up with 40 mL DMEM/F12 media contained 10% fetal bovine serum, 1X GlutaMAX and 1X
PenStrep. Culture medium was changed once after 72 h by removing half of the volume and replaced
it with fresh media.
2.5. Real Architecture for 3D Tissue (RAFT) Culturing
Three-dimensional real architecture for 3D tissue (RAFT) cultures were prepared following
the instructions of the manufacturer (Lonza, Basel, Switzerland) as described previously [15].
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Briefly, the components of the kit (Type I rat tail collagen, 10X MEM culture medium, neutralization
solution) and cell suspension were gently mixed and aliquoted into the 96-well plate (240 µL mix per
well, 4000 cells per well) and placed into the CO2 cell culture incubator (37 ◦C, 5% CO2) for 15 min to
form the collagen hydrogel. The hydrophilic RAFT absorbers were placed onto the top of hydrogels
and left for 15 min to absorb the free fluids from the collagen discoids. Finally, the wells were filled up
with 200 µL cell culture media, and the plates were placed in the cell culture incubator under standard
culture conditions (5% CO2, 37 ◦C). RAFT cultures were pooled for experiments at equivalent cell load
compared to other cell culture methods.
2.6. A549 Xenograft Tumor Model
For gene expression measurements 1 × 106 A549 cells in 100 µL FBS free DMEM/F12 were
injected subcutaneously into 8-weeks-old NOD SCID mice (Innovo Ltd., Isaszeg, Hungary). A few
weeks later when the xenograft tumors reached the volume of 80–100 mm3, the mice were sacrificed,
and subcutaneous tumor tissues were excised and processed for gene expression analysis.
For mass cytometry (Helios, Fluidigm, San Francisco, CA, USA) measurements the 8-weeks-old
NOD SCID mice (n = 6) were injected subcutaneously with 1 × 106 A549 cells in 100 µL FBS free
DMEM/F12 and the mice were sacrificed at two different time points, three of them after 30 days,
when the tumor reached volume of 80–100 mm3 (early stage, non-necrotic small tumors) and another
three mice after 60 days, when the tumor reached volume of 1000–1200 mm3 (late stage, necrotic tumors).
All mouse studies were done in accordance with national and international laws and regulations
of animal experiments and were reviewed and approved by the Regional Animal Health Authorities,
Csongrad County, Hungary, and by the Joint Local Ethics and Animal Welfare Committee of Avidin
Ltd. in possession of an ethical clearance XXIX./128/2013.
2.7. Imaging
Digital phase contrast images were taken by the HoloMonitor M3 instrument using phase
contrast X10 objective (Phase Holographic Imaging AB, Phiab, Sweden) and the analysis computer
(HoloStudio 2.0 software, Phiab, Sweden). Phase contrast images were used as a reference to confirm
that the cells were in good condition under the studied period. Changes were analyzed at days 4 and 9.
2.8. Cell Proliferation Assay
The proliferation of A549 cells was determined by the fluorescent resazurin (Sigma-Aldrich) assay
as described previously [28]. Briefly, an aliquot of all types of cells (6000) pre-cultured in either different
3D or 2D conditions were removed and seeded into 96-well plates (Corning Life Sciences) in DMEM/F12
10 % FBS (Gibco) in order to perform the viability assay every day. Resazurin reagent (Sigma-Aldrich)
was dissolved in PBS (pH 7.4) at 0.15 mg/mL concentration, 0.22 µm filtered and aliquoted at −20 ◦C.
We applied resazurin 20 µL stock to 100 µL culture. After 2 h incubation at 37 ◦C under 5 % CO2
(Sanyo) fluorescence (530 nm excitation / 580nm emission) was recorded on a multimode microplate
reader (Cytofluor4000, PerSeptive Biosytems, Framingham, MA, USA). Proliferation was calculated
with relation to blank wells containing media without cells. (Significance was compared to 2D TC,
pairwise. RFU = relative fluorescence unit)
2.9. Cell Cycle Analysis
Cells were released from all cultures by digestion with 1 mg/mL collagenase IV (Sigma-Aldrich)
for 30 min for 3D and 5 min for 2D at 37 ◦C, manually shaken in serum-free DMEM (Gibco),
12 RAFT discoids were pooled for one flow cytometric sample. Cell cycle analysis was performed as
described previously [29]. Briefly, the cells (50,000) cultured under different conditions were collected,
washed with PBS and resuspended in DNA binding buffer (1X PBS, 0.1% tri-sodium-citrate, 10 µg/mL
PI, 0.1% Triton X-100, 10 µg/mL RNaseA, Sigma-Aldrich) on days 4 and 9. After 30 min incubation at
room temperature cells were acquired on a FACSCalibur cytofluorimeter (Becton Dickinson, Franklin
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Lakes, NJ, USA), sub-G1 apoptotic population was analyzed on FL3 histograms using CellQuest
software (Becton Dickinson). Doublets were gated out for cell cycle analysis which was based on
FL2-A/FL2-W dot plots, using Modfit software version 3.2 (Becton Dickinson).
2.10. Apoptotic Assay
Cells were released from all cultures by digestion with 1 mg/mL collagenase IV (Sigma-Aldrich)
for 30 min for 3D and 5 min for 2D at 37 ◦C, manually shaken in serum-free DMEM (Gibco), 12 RAFT
discoids were pooled for one assay sample. Apoptosis was detected as described previously [30].
Briefly, cells cultured under different conditions were collected and resuspended in Annexin V
binding buffer (0.01 M HEPES, 0.14 M NaCl and 2.5 mM CaCl2, Sigma-Aldrich) on the 4th and
the 9th day. Annexin V-Alexa 488 (Thermo Fisher Scientific, 2.5:100) was added to the cells, which
were then kept in dark at room temperature for 15 min. Before the acquisition, propidium iodide
(10 µg/mL) (Sigma-Aldrich) was added in Annexin V binding buffer to dilute Annexin V-Alexa 488 5X.
Cells were analyzed on a FACSCalibur cytofluorimeter using CellQuest software (Becton Dickinson).
The percentage of the FL1 (AnnexinV-Alexa 488, AnnV) negative and FL3 (propidium iodide, PI)
negative living cells (AnnV−/PI−), the early apoptotic (AnnV+/PI−), late apoptotic (AnnV+/PI+) and
necrotic (AnnV−/PI+) cells were determined.
2.11. Profiling of RNAs with High-Throughput, Nanocapillary qRT-PCR
Nanocapillary qRT-PCR was performed as described previously with some modifications [31,32].
The gene expression profile of two-dimensional standard culture of A549 cells (70% confluent in
standard tissue culture Petri-dish, 2D monolayer) were compared to xenografts. Supernatant was
removed from the 2D monolayer, cells were washed two times by 1 mL of PBS, then 1 mL AccuZol™
Total RNA Extraction Solution was added for homogenization per sample. Solid tumors were removed
surgically (at 80 mm3 volume), cut into 2 pieces and one half placed into RNAlater (Thermo Fisher
Scientific). Tumor tissue was homogenized by Tissue Homogenization Set (Bioneer, Daejeon, Korea).
RNA was purified from both 2D and ex vivo samples by Direct-zolTM MiniPrep Plus (Zymo Research,
Irvine, CA, USA). The quantity of total RNA was measured by NanoDrop 1000 spectrophotometer
(Thermo Fisher Scientific). For nanocapillary qRT-PCR total RNA (2 µg) was converted into cDNA
with the High-Capacity cDNA RT Kit (Thermo Fisher Scientific) and without purification the mixture
was diluted with RNase-free water. Amplification of the samples was followed in real time with
QuantStudio™ 12K Flex System (Thermo Fisher Scientific). To determine the gene expression changes
TaqMan® OpenArray® Human Cancer Panel was used. This gene signature panel targets 624
well-defined genes validated as markers for pluripotency, DNA repair, angiogenesis, cell adhesion,
apoptosis, and extracellular matrix, as well as genes involved in the cell cycle plus 24 endogenous
control genes. The format of the OpenArray® plate allows for 4 replicates to run in parallel per
plate (2-2 biological replicates were analyzed on a slide). The cancer panel gene list is available in
Supplementary Materials File 1.
The reverse transcribed samples (or water for no template controls) were added to a 384-well
plate containing TaqMan® OpenArray® Real-Time PCR Master Mix (Thermo Fisher Scientific) for
OpenArray® amplification. The OpenArray® autoloader transfers the cDNA/master mix from the
plate to the array through-holes by capillary action. Each subarray was loaded with 5 µL of reaction
mix containing 1.2 µL of reverse transcribed cDNA resulting in 33 nL final reaction volume containing
0.8 ng cDNA. The array is manually transferred to the OpenArray® slide case and sealed. The plates
were cycled in the OpenArray® cycler under the following conditions: 50 ◦C for 15 s, 91 ◦C for 10 min,
followed by 50 cycles of 54 ◦C for 170 s and 92 ◦C for 45 s.
The QuantStudio 12K Flex software uses a proprietary calling algorithm that estimates the quality
of each individual threshold cycle (Ct) value by calculating a Ct confidence value for the amplification
reaction. In our assay, Ct values with Ct confidence values below 300 (average Ct confidence of the
non-target amplification reactions plus 3 standard deviations) were considered background signals.
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Higher Ct confidence levels were considered positive and were analyzed further. Normalization was
done by using the Ct value of HPRT1 house-keeping gene (∆Ct = Ctgene −CtHPRT1) and gene expression
changes were calculated from two replicates. Data are expressed as ∆∆Ct (log2) values and were
normalized to expression values from cells maintained in standard tissue culture Petri-dish (monolayer);
(∆∆Ct (log2) = ∆Ctmonolayer − ∆Ctin vivo). Average values were accepted when the standard deviation
(SD) was below 0.5-fold of the average. Expression data (∆∆Ct ± SD, p) for 60 selected genes are in
Table 2, for 648 genes are available in Supplementary Materials File 1.
2.12. Gene Expression Analysis by High-Throughput qRT-PCR
Cells were released from all cultures by digestion with 1 mg/mL collagenase IV (Sigma-Aldrich)
for 30 min for 3D and for 5 min for 2D at 37 ◦C, manually shaken in serum-free DMEM (Gibco),
RAFT discoids were pooled for one sample. Reference sample was the standard culture of A549 cells
(70% confluent in standard tissue culture Petri-dish, 2D monolayer). High-throughput qRT-PCR was
performed as described previously [33]. Briefly, on 4th and 9th day the cells cultured under different
conditions were collected, centrifuged (3000 rpm, 5 min) and total RNA was purified using AccuPrep
Viral RNA Extraction kit (Bioneer) with a modified protocol. Briefly, cells were lysed with RA1 lysis
buffer (Macherey-Nagel, Düren, Germany) and applied to the Viral RNA Extraction binding tube and
then washed and eluted with the protocol recommended by the manufacturer. The quantity of total
RNA was measured by NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). Total RNA
(6µg) was converted into cDNA with the High-Capacity cDNA Archive Kit (Applied Biosystems,
Foster City, CA, USA) in a total volume of 60µL.
The qPCR reactions were prepared by the Agilent Bravo Liquid Handling Platform
(Agilent Technologies, Santa Clara, CA, USA) according to manufacturer’s recommendations. Each 2µL
reaction mixture contained 6 ng cDNA, 10 pmol gene-specific primers, and 1µL 2× LightCycler1536
Probes Master (Roche, Basel, Switzerland). List of primers is available in Supplementary Materials
File 2. Amplification was performed on the LightCycler 1536 System (Roche) using 64 pre-selected
genes. The panel consists of 62 tumor-related genes with two human reference genes (GAPDH and
HPRT1). During the amplification the following protocol was used: 95 ◦C for 1 min, 60 cycles of
95 ◦C for 10 s, and 60 ◦C for 10 s, followed by 40 ◦C for 10 s final cooling. Data were collected and
processed using the LightCycler 1536 SW 1.0 software (Roche). Relative expression of the analyzed
genes was normalized to the mean value of the HPRT1 reference gene (∆Ct = Ctgene − CtHPRT1) and
gene expression changes were calculated from four replicates. Data are expressed as ∆∆Ct (log2) values
and were normalized to expression values from cells maintained in standard tissue culture Petri-dish
(monolayer); (∆∆Ct (log2) = ∆Ctmonolayer − ∆Ct2D or 3D cultures). Expression data (∆∆Ct ± SD, p) for all
62 genes are available in Supplementary Materials File 3.
2.13. Cluster Analysis
Cluster analysis (hierarchic) was performed by Gene Cluster 3.0 software (University of
Tokyo, Tokyo, Japan) from expression data (∆∆CT, log2 values) of cells maintained under different
culture conditions.
2.14. Single Cell Mass Cytometry
A549 cells were maintained under the following tissue culture conditions: long term (9 days) (1)
standard tissue culture (10 mm diameter cell culture Petri-dish (Corning, 2D monolayer), (2) grown
on Cytodex3 or (3) Nutrisphere beads (3D) and injected into SCID mice to form (4) early and (5) late
stage tumors. Cells were washed with PBS and liberated by Accutase (Corning Life Sciences) from
2D monolayer and 3D cultures. Tumor tissues were homogenized mechanically using scissors and
tweezers. Small pieces were incubated with Accutase for 60 min at room temperature. Samples were
loaded on cell strainer (100 µm in pore size, VWR, Radnoe, PA, USA) and washed by PBS. Cells were
counted using Bürker chamber and trypan blue viability dye. Three million cells pooled from three
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biological replicates were processed for mass cytometry staining in suspension in PBS. Viability of
the cells was determined by cisplatin (5 µM 195Pt, Fluidigm) staining for 3 min on ice in 300 µL PBS.
Sample was diluted by 1500 µL Maxpar Cell Staining Buffer (MCSB) and centrifuged at 350 g for 5 min.
Cells were suspended in 50 µL MCSB and the following antibody mix (Table 1) was added in 50 µL.
Table 1. Antibodies used for mass cytometry.
Catalogue Number Supplier Target Metal Tag
3144017B Fluidigm HLA-A,B,C 144_Nd
3141006B Fluidigm CD326 (EpCam) 141_Pr
3148012B Fluidigm TRA-1-60 148_Nd
3149018B Fluidigm CD66-a,c,e 149_Sm
3156026B Fluidigm CD274 (PD-L1) 156_Gd
3162027A Fluidigm Pan-Keratin 162_Dy
3166007B Fluidigm CD24 166_Er
3170009B Fluidigm EGFR 170_Er
3153026B Fluidigm Galectin-3 (Gal-3) 153_Eu
MAB2188-100 R&D Systems CA9 158_Gd
MAB1418 R&D Systems GLUT1 154_Sm
sc-376140 Santa Cruz Biotech. MCT4 171_Yb
orb357227 Biorbyt TMEM45A 169_TM
The following antibodies were conjugated with metal tags in house: anti-CA9, anti-GLUT1,
anti-MCT4 and anti-TMEM45A using Maxpar metal labeling kit strictly according to the instructions
of the manufacturer (Fluidigm). Antibodies were titrated prior to the experiment in order to determine
the optimal dilution.
Samples after 60 min incubation at 4 ◦C, antibodies were washed by 2 mL MCSB and centrifuged
at 300 g 5 min, two times. The pellet was suspended in the residual volume. Cells were fixed in 1.6 %
formaldehyde (freshly diluted from 16% Pierce formaldehyde with PBS, Thermo Fisher Scientific) and
incubated for 10 min at room temperature. Cells were centrifuged at 800 g for 5 min. Cell ID DNA
intercalator (191/193 Iridium, Fluidigm) was added in 1000× dilution in Maxpar Fix and Perm for
overnight at 4 ◦C. Cells for the acquisition were centrifuged at 800 g for 5 min then were washed by
2 mL MCSB and centrifuged at 800 g for 5 min. Cells were suspended in 1 mL PBS (for WB injector) and
counted in Bürker-chamber during centrifugation. For the acquisition, the concentration of cells was
set to 0.5 × 106/mL in cell acquisition solution (CAS) containing 10% EQ Calibration Beads. Cells were
filtered through 30 µm gravity filter (Celltrix, Uppsala, Sweden) and acquired freshly. Mass cytometry
data were analyzed in Cytobank (Beckman Coulter, Brea, CA, USA). Single living cells were determined
(1 × 105 for 2D and early stage in vivo tumors; 3 × 105 for 3D models and 5 × 105 events for late in vivo).
viSNE (visualization of stochastic neighbor embedding) analysis (iterations = 1000, perplexity = 30,
theta = 0.5), was carried out on 4.5 × 104 HLA-A,B,C+ events for all samples excluding stromal cells of
the A549 xenografts [34].
2.15. Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6 (Sandiego, CA, USA) and Microsoft
Excel (Redmond, WA, USA). Paired t-test was performed between two groups as indicated in the
figure legends. Data were expressed as arithmetic mean ± standard deviation (SD).
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3. Results
3.1. Long-term Growth Curve, Apoptosis, and Cell Cycle Phase Distribution of 3D Cultures
Non-small cell lung carcinoma A549 cells were cultured under different conditions for 4 days as
short term (Figure 1A) and for 9 days as long-term (Figure 1B) in order to analyze whether different
incubation times affect growth kinetics, viability and cell cycle changes in these 2D and 3D cultures.
Seeding of A549 cells on two-dimensional tissue culture T-75 flasks (2D TC) was used as a reference
standard. Other T-75 flasks were coated with collagen type I (2D Coll) as a control for collagen-based
3D models. Three-dimensional culturing has been performed in two different ways: one with a special
instrument, the BioLevitator system, where cells were levitated and the other was collagen embedding
in RAFT system. To generate different types of multicellular spheroids in the BioLevitator system,
microcarrier free (3D Spheroid) and microcarrier based models were used (bead-based 3D Cytodex3
and 3D Nutrisphere, Figure 1). The cultivation of cells was performed under the same conditions:
surface/volume ratio, cell culture media, glucose concentration, pH, pCO2 and pO2 tension either for
2D or 3D models. Representative images illustrate A549 cells in different cultures for 4 (Figure 1A) and
9 days (Figure 1B), respectively.
Figure 1. Different culture conditions of A549 human adenocarcinoma cells for 4 days (A) and for 9
days (B). Cells were seeded at the same surface/volume ratio regarding the different culture conditions
as described in Materials and Methods. Images were taken by the HoloMonitor M3 instrument using
phase contrast X10 objective. Scale bar: 150 µm.
Using resazurin cell proliferation assay the growth kinetics of differently formed 3D spheroids
and 2D cultures were compared. The assay showed that cells in 2D cultures (2D TC, 2D Coll) reduced
resazurin to resorufin more intensely proportionally with a higher number of cells than any of the
used 3D models (Figure 2A). Both monolayer 2D cultures reached the plateau phase on day 4. The 3D
spheroids grown on the surface of the Nutrisphere’s magnetic beads (3D Nutrisphere) reached the
plateau only on day 8, while the spheroids grown on Cytodex3 microcarriers (3D Cytodex3) or the ones
embedded into ECM matrix (RAFT) reached the same state on day 6. On the other hand, the carrier-free
3D Spheroids did not reach stationary phase in the duration of the experiment. These spheroids
cultured without microcarriers grew very slowly and formed only small multicellular spheroids
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consisting of 50–100 cells. Thus, these spheroids were in an early stage of multicellular tumor formation
(Figure 2A).
Figure 2. Proliferation rate, viability and apoptosis of A549 cells under different culture conditions.
(A) Cells grow slowly in 3D culture than in 2D cultures on culture day 4 (3D spehorids p ≤ 0.0001;
RAFT, 3D Cytodex3 and 3D Nutrisphere p ≤ 0.01), but on day 9 only the 3D Spheroid (p ≤ 0.01) and 3D
Cytodex3 (p ≤ 0.05) showed significantly lower cell numbers than 2D cultures. (n = 3, paired t-test).
The viability of cells (AnnV−/PI− living population) remained around 80–90% at day 4 (B) and day 9
(C), only RAFT culturing resulted in 50% decrease in viability at day 9. Insert shows representative
dot plots of single cells for SSC-FSC (Side scatter-Forward scatter, B left insert) and for quadrants
detecting living cells (AnnV−/PI−), early apoptotic cells (AnnV+/PI-), late apoptotic cells (AnnV+/PI+)
and necrotic cells (AnnV−/PI+) (B right insert). Data are mean ± SD of three replicates.
At two timepoints, when the growth of 2D cultures reached the plateau stage (day 4) and at the
end of the experimental period (day 9) (Figure 2A), six types of 2D and 3D in vitro cultures were
harvested as single cell suspension for flow cytometric analysis of viability (apoptosis) (Figure 2B,C)
and cell cycle phase distribution (Figure 3). The viability of cells calculated from the percentage of cells
without PI staining remained above 90% at both day 4 (Figure 2B) and day 9 (Figure 2C) except RAFT
collagen embedding. Flow cytometric analysis showed that RAFT culturing resulted in 50% decrease
in viability at day 9 (Figure 2C).
Figure 3. Cell cycle phase distribution of A549 cells cultured under different conditions at the 4th (A)
and the 9th culturing days (B). Insert shows PI signal of single cells FL2-A (area)-FL2-W (width) gating
out aggregates (A left insert) and a representative image of cell cycle phases (A right insert). Data are
mean ± SD of three replicates except RAFT where 12 collagen discoids were pooled.
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The ratio of G0/G1 and S (DNA synthesis) cell cycle phases did not differ significantly among the
used 2D and 3D culture conditions either at day 4 (Figure 3A) and day 9 (Figure 3B). Cultures of 2D
Coll, 3D Cytodex3, 3D Nutrisphere and RAFT showed higher population of cells in G2/M at day 4
(Figure 3A) which was not present at day 9 (Figure 3B).
3.2. Selection of Genes with Differential Expression In Vivo and in 3D Models Compared to Monolayer Cultures
Gene expression analysis was carried out in two steps. First gene expression changes were
determined between in vitro monolayer culture and in vivo A549 xenograft cancer cells by high
throughput TaqMan® OpenArray® Human Cancer Panel. Next, genes with differential expression
were selected from the first analysis and were measured on the LightCycler 1536 HTS qPCR System
for each in vitro 2D and 3D culture. Nanocapillary, quantitative real-time PCR (qRT-PCR) has
been previously successfully used in our laboratory in toxicogenomics screening to cluster toxic
compounds [31] and to predict organ-specific toxicity [35]. Here we performed the comparative
investigation of gene expression of murine A549 xenografts (80–100 mm3) and monolayer cultures
(A549 cell maintained in standard Petri-dish with 70% confluence) using a commercial Cancer Panel
for 624 genes and 24 housekeeping genes (listed in Supplementary Materials File 1) in order to
pre-select candidates for the subsequent qRT-PCR analysis on all 2D and 3D culture conditions under
investigation. The TaqMan® OpenArray® Human Cancer Panel contains validated markers for
pluripotency, DNA repair, angiogenesis, cell adhesion, apoptosis, ECM and cell cycle. Sixty genes
which showed overexpression (29 genes, Table 2, pink) or downregulation (31 genes, Table 2, green) in
A549 non-small cell lung tumors compared to A549 monolayer cultures have been selected for further
studies. Expression data (∆∆Ct ± SD, p) of A549 xenograft compared to monolayer cultures for the
whole panel (648 genes) are available in Supplementary Materials File 1.
Primer pairs were designed for the in vivo differentially expressed 60 genes identified by Open
Array nanocapillary qRT-PCR, and SLC2A1 (GLUT1) and SLC16A3 (MCT4) in order to investigate the
transcriptome of different 2D and 3D cultures by 1536 well high-throughput qRT-PCR (list of primer
pairs can be found in Supplementary Materials File 2). Two key players of tumor cell metabolism,
the lactate transporter SLC16A3 (MCT4) and glucose transporter SLC2A1 (GLUT1) were included
because these probes were not present in the cancer panel, but it has been reported that high MCT4
and GLUT1 expression is associated with poor overall survival of adenocarcinoma patients [36].
Both early (day 4,) and late (day 9,) culture time points were analyzed (Figure 4). Gene expression data
(∆∆Ct ± SD, p) of different 2D and 3D cultures can be found in the Supplementary Materials File 3.
The characterization of genes in 2D and 3D cultures under investigation facilitated the design of an
antibody panel for the subsequent single cell mass cytometry. Markers localized to the cell surface
with well-characterized antibodies available on the market were selected. While SLC16A3 (MCT4),
SLC2A1 (GLUT1) and CA9 have been reported in metabolic reprogramming of malignant cells [37],
the others have been shown to support tumor progression and chemoresistance via maintaining cancer
stemness, epithelial-mesenchymal transition: CEACAM5, CD24 [38,39] or via driving proliferation:
TMEM45A [40], EGFR [41]. With the exception of EGFR, all markers showed 16–32-fold overexpression
in three-dimensional bead-based cultures: the 3D Cytodex3 and 3D Nutrisphere compared to 2D
monolayer in long-term cultures (d9) (Figure 4). At the day 9 collagen embedded RAFT and carrier-free
spheroids behaved differently from bead-based cultures with very little change, except CEACAM5,
where 3D Spheroids showed 8 times induction of expression (Figure 4). Gene expression analysis was
not performed on RAFT d4 samples due to the limited amount of isolated RNA from cultured cells.
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Table 2. Gene expression analysis by nanocapillary qRT-PCR of 624 genes (TaqMan® OpenArray® Human Cancer Panel, QuantStudio™ 12K Flex) of A549 xenografts
(in vivo) compared to 2D monolayer (Petri-dish) cultures resulted in the selection of sixty genes: 29 upregulated (pink) and 31 downregulated (green) for further
studies. Significance (p) was calculated by Student’s t-test as pairwise comparison of ∆Ct values.
Gene Symbol Assay ID ∆∆Ct (log2) SD Significance (p) Gene Symbol Assay ID ∆∆Ct (log2) SD Significance (p)
CEACAM5 Hs00944025_m1 9.11 1.77 0.0220 JUN Hs00277190_s1 −2.34 1.97 0.2740
APPL1 Hs00179382_m1 8.17 0.12 0.0001 MYC Hs99999003_m1 −2.42 1.96 0.2306
LCN2 Hs01008571_m1 5.58 0.68 0.0082 MKI67 Hs01032443_m1 −2.43 0.45 0.0249
SEPP1 Hs01032845_m1 5.26 1.10 0.0293 FTL Hs00830226_gH −2.51 1.21 0.1293
PRDX2 Hs03044902_g1 4.71 1.45 0.0590 CTPS Hs00157163_m1 −2.53 1.41 0.1831
TGFBR1 Hs00610318_m1 4.38 0.02 0.0001 E2F1 Hs00153451_m1 −2.63 1.58 0.1555
CP Hs00236810_m1 4.36 0.08 0.1173 PFKP Hs00242993_m1 −2.64 1.70 0.1746
ANPEP Hs00952642_m1 3.79 2.19 0.2148 FBN2 Hs00266592_m1 −2.65 0.17 0.2083
DLG3 Hs00221664_m1 3.72 0.22 0.0213 CYR61 Hs00155479_m1 −2.79 2.20 0.2390
CA9 Hs00154208_m1 3.71 1.42 0.0886 CTSL2 Hs00822401_m1 −2.81 1.03 0.0769
CD24 Hs00273561_s1 3.66 0.54 0.0182 EGFR Hs01076078_m1 −2.82 0.38 0.0345
IFITM1 Hs00705137_s1 3.60 0.25 0.0057 IGFBP4 Hs00181767_m1 −2.83 1.73 0.1601
PECAM1 Hs00169777_m1 3.54 0.00 0.0217 FGFR1 Hs00241111_m1 −2.87 1.74 0.2655
MX1 Hs00895608_m1 3.53 0.92 0.0702 AXL Hs01064444_m1 −2.87 1.81 0.1685
TMEM45A Hs01046616_m1 3.49 1.42 0.2538 ASNS Hs00370265_m1 −2.98 1.02 0.0890
KRT19 Hs00761767_s1 3.38 1.35 0.0793 SOCS3 Hs02330328_s1 −3.04 1.01 0.1962
TLR3 Hs00152933_m1 3.37 0.48 0.0330 IER3 Hs00174674_m1 −3.18 1.78 0.2419
ERBB3 Hs00176538_m1 3.27 0.95 0.0524 CDC25B Hs01550934_m1 −3.20 1.51 0.1116
IGFBP5 Hs01052296_m1 3.18 1.03 0.0563 BAX Hs00180269_m1 −3.32 1.22 0.0804
CDKN1B Hs00153277_m1 2.91 0.22 0.0217 TFAP2C Hs00231476_m1 −3.60 1.58 0.0921
SFN Hs00968567_s1 2.83 0.61 0.0329 ABCG2 Hs01053790_m1 −3.66 0.85 0.0368
HYAL1 Hs00201046_m1 2.74 0.38 0.0096 NR4A1 Hs00374226_m1 −3.66 0.83 0.0250
MYB Hs00920554_m1 2.54 1.61 0.2887 RAB6B Hs00981572_m1 −3.66 0.89 0.0446
PDGFB Hs00966522_m1 2.47 0.47 0.0853 CD70 Hs00174297_m1 −3.94 0.00 0.1385
ERBB2 Hs01001580_m1 2.40 1.25 0.1180 CSF1 Hs00174164_m1 −4.03 0.19 0.0107
GRB7 Hs00918009_g1 2.39 0.67 0.3032 FYN Hs00176628_m1 −4.09 1.86 0.0988
FN1 Hs01549976_m1 2.38 1.25 0.1188 PLCG2 Hs00182192_m1 −4.13 2.19 0.1465
CEBPG Hs00156454_m1 2.37 1.99 0.5677 EGR1 Hs00152928_m1 −4.19 2.60 0.1582
IGFBP3 Hs00181211_m1 2.34 1.03 0.1114 ID1 Hs03676575_s1 −4.38 0.22 0.0155
ADM Hs00181605_m1 −4.51 0.10 0.0013
FOS Hs00170630_m1 −4.61 2.40 0.1254
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Figure 4. Gene expression changes after 4 (d4) and 9 days (d9) of culture under different 2D and 3D
conditions. Selected genes having cell surface localized protein product and well characterized antibody
available on the market: TMEM5A, SLC16A3 (MCT4), CEACAM5, SLC2A1 (GLUT1), and CA9 showed
16–32 times overexpression in 3D Cytodex3 and 3D Nutrisphere compared to 2D monolayer. Data are
mean ± SD of three replicates.
In order to determine the closest culture method that mimicked the in vivo gene expression
profile of non-small cell lung cancer cells, hierarchical clustering was performed on both days 4 and
9 of all the studied 2D and 3D culture methods (Figure 5). Short-term cultures (d4) of 2D TC, 2D
Coll, 3D Cytodex3, 3D Nutrisphere, and 3D Spheroid represent a sub-cluster separate from long-term
cultures and xenografts (in vivo) (Figure 5). Long-term (d9) maintenance of three-dimensional cultures
(3D Spheroid, 3D Nutrisphere, 3D Cytodex3) clustered close to xenografts suggesting a closer relation
to the in vivo situation (Figure 5). Cultures which are difficult to handle for high number of cells
(RAFT) or difficult to standardize (3D Spheroids) were ignored in the subsequent experiments.
Figure 5. Long-term (day 9, d9) maintenance of 3D cultures (3D Spheroid, 3D Nutrisphere, 3D Cytodex3)
mimic the in vivo situation better. The highlighted genes (black squares) were selected for subsequent
analysis by single cell mass cytometry. Cluster analysis (hierarchical) was performed by Gene Cluster
3.0 software from expression data (∆∆Ct, log2 values) of presented samples.
3.3. Single Cell-based Profiling Provides a Characteristic Map of Lung Cancer Markers
Twelve cancer markers were studied by single cell mass cytometry from long-term (9 days) 2D
monolayer and 3D Cytodex3, 3D Nutrisphere cultures and compared to early and late stage solid A549
tumors. Seven protein markers: TMEM45A, MCT4, CD66 (CEACAM5), GLUT1, CA9, CD24, EGFR
were selected by their gene expression profile or their known relevance detailed above. Five additional
proteins were studied: carcinoma stem cell markers: TRA-1-60 [42], CD326 (epithelial cell adhesion
molecule, EpCAM) [43], galectin-3 (GAL-3) [44], the immune checkpoint inhibitor CD274 (programmed
cell death ligand-1, PD-L1) [45] and carcinoma marker pan-keratin (cytokeratins) [46]. The relevance
of the studied proteins was validated in two other NSCLC cell lines (H1975 and H1650) by mass
cytometry (unpublished data). Although keratins are the building blocks of type I and II intermediate
filaments of epithelial cells [46], it has also been published that these can localize to the outer surface
of cancer cells to enhance cell adhesion to the ECM [47,48]. Representative multi-dimensional data
analysis (visualization of stochastic neighbor embedding, viSNE, [34]) reveals cell-relatedness based
on common marker expression by simultaneous analysis of all 12 markers at single cell resolution
(Figure 6).
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Figure 6. Representative multidimensional visualization of stochastic neighbor embedding (viSNE)
analysis of 12 protein markers at single cell resolution in 2D, 3D (3D Cytodex3 or 3D Nutrisphere)
cultures and in vivo (early or late stage) tumors. The analysis was performed within 4.5 × 104
HLA-A,B,C positive cells in case of all conditions in order to identify human A549 cells in the xenografts
and exclude murine stromal cells. (iterations = 1000, perplexity = 30, theta = 0.5).
Single cells are mapped based on the expression of all 12 markers within each condition.
Analysis was performed within 4.5 × 104 HLA-A,B,C positive cells in case of all conditions in
order to determine human A549 cells in the xenografts and exclude murine stromal cells. A549 cells
(2D monolayer) were previously tested for HLA-A,B,C expression with 99.9% positivity (Supplementary
Figure S4). The expression level of each marker is coded by the shown color-scale with blue representing
low, while red, high values (Figure 6). Nine out of twelve markers (TRA-1-60, TMEM45A, pan-keratin,
CD326, MCT4, GAL-3, CD66, GLUT1, CA9) were absent or showed relatively very weak expression
in the 2D monolayer culture of A549 cells (Figure 6A,B, first columns). The pattern of three markers
showed intra-cell line heterogeneity of standard Petri-dish based cultures by moderate (CD24, CD274)
or strong (EGFR) protein load on the cell surface (Figure 6B, first column). Single cell proteome profiles
of each three-dimensional culture (3D Cytodex3 and 3D Nutrisphere) represent a transition from 2D to
the in vivo situation by intermediate marker expression in case of 9 proteins (TRA-1-60, TMEM45A,
pan-keratin, CD326, MCT4, GAL-3, CD66, GLUT1, CD274) (Figure 6A,B, second and third columns).
In bead carrier-based systems, three markers (CA9, CD24, EGFR) were exposed to the cell surface
higher to in vivo (Figure 6B, second and third columns). All twelve markers drew the map of lung
cancer cells in vivo as a different islet from the population of cells from 2D and 3D samples with a
unique pattern reflecting intra-tumor heterogeneity on viSNE plots (Figure 6A,B, fifth columns).
Merging viSNE graphs of 2D, 3D and in vivo samples by multiparametric (12 proteins) single
cell mass cytometry results delineate a map with three different ‘islands’ representing 2D, 3D and
in vivo conditions with minimal overlap (Figure 7). Both segmentation and the area of the maps are
proportional with heterogeneity of single cells in terms of the expression of the twelve studied tumor
markers within a cohort. Standard 2D as the smallest tSNE island represents the poorest heterogeneity
far from the 3D or in vivo condition.
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Figure 7. Merging viSNE graphs of multiparametric single cell mass cytometry data (12 parameters)
of 2D, 3D and in vivo samples delineates a map with three different islands of 2D, 3D, and
in vivo conditions.
In order to quantify marker expression at population level, percentage of HLA-A,B,C positive
cells (A549) from a representative experiment were plotted on trajectories of radar plots among five
different conditions: (I) 2D monolayer, (II) 3D Cytodex3, (III) 3D Nutrisphere, (IV) early and (V)
late stage in vivo adenocarcinoma (Figure 8A). The trajectories show the percentage of A549 NSCLC
(gated on HLA-A,B,C positive cells in order to exclude murine stroma) cells in the range of 0–100%
for the positivity (expression) of each studied marker (Figure 8A). The following proteins determine
trajectories within the pentagram to localize to advanced cancer (Figure 8): TRA-1-60 (9%), TMEM45A
(37.5%), pan-keratin (50%), CD326 (100%), MCT4 (50%), GAL-3 (30%), CD66 (100%), GLUT1 (100%)
(Figure 8A). Cells positive for CA9 have the highest population (100%) in 3D models probably due to
the lack of circulation. Compared to monolayer condition, cancer stem cell marker CD24 and EGFR
decreased in vivo from 70% to 35% and 100% to 25%, respectively. CD274 positive cells were 40 % in
2D and 25 % in vivo with weak expression in 3D models (Figure 8A).
Figure 8. (A) Trajectories tend to localize to early and late stage tumors in the case of TRA-1-60, TMEM45A,
pan-keratin, CD326, MCT4, GAL-3, CD66, and GLUT1. Percentage of HLA-A,B,C positive cells (A549) from
a representative experiment were plotted on trajectories among five different conditions: (I) 2D monolayer,
(II) 3D Cytodex3, (III) 3D Nutrisphere, (IV) early and (V) late stage in vivo adenocarcinoma. (B) Heatmap of
mass cytometry data regarding protein density at single cell resolution among the five different conditions
normalized to 2D monolayer (green: low, red: high expression).
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Regarding protein density at single cell resolution, median values in all channels within HLA-A,B,C
positive cells were normalized to reference 2D monolayer sample and visualized as a heatmap of
studied proteins (Figure 8B). Three-dimensional cultures represent a transition from 2D to in vivo
situation in terms of lung cancer marker expression, only TRA-1-60, TMEM45, pan-keratin and CD326
have intensity values (median) much below the value of the cells in vivo (Figure 8B).
4. Discussion
Genomics and proteomics opened new avenues for drug discovery with the emergence of novel
therapeutic and diagnostic targets. Recent achievements in drug discovery with the combination of
innovative 3D cell culture techniques yielded high-throughput screening (HTS) methodologies of 3D
cellular assays in the pre-clinical phase of the drug discovery pipeline. These 3D HTS assays provide
information not only on a general cellular response (cytotoxicity) to a given drug, but could map a
signal transduction machinery or monitor the cellular response at transcriptional/translational level in
a model system closer to the in vivo situation [49]. Monolayer cultures are oversimplified models of a
multicellular organism. Beyond their benefits, they fail to present the in vivo situation in several aspects
such as the flow of cellular metabolites, partial oxygen tension, the gradient of soluble mediators,
whereas 3D tissue culture models have a closer resemblance to the in vivo conditions [50]. In 3D models
oxygen and nutrient deprivation results in higher glycolytic activity, elevated autophagy and necrosis
induced by anaerobic conditions [51–54]. Active signaling pathways are also different between 3D and
2D cultures for the lack of complexity of cell-cell and cell-ECM connections (integrins, proteoglycans)
present in multicellular organism [55,56]. Different studies show that multicellular spheroid formation
highly influenced extracellular matrix protein expression [57,58] and relevant gene expression levels as
well [59,60].
In order to find the most suitable 3D culture method to mimic in vivo tumor biology we performed
comparative analysis of different 2D (2D standard Petri-dish; tissue culture-treated T-75 flasks, 2D TC;
type I collagen coated plates, 2D Coll); 3D bead-based (3D Cytodex3, 3D Nutrisphere); 3D carrier-free
(3D Spheroid) and collagen embedding (RAFT) cell culture methods (Figure 1). These culture methods
were compared to A549 xenograft tumors (in vivo). Both short-term (day 4) and long-term (day 9)
cultures were analyzed with early stage and late stage adenocarcinoma.
The investigation of the proliferation rate in different culture methods revealed that carrier-free
spheroids divided less frequently with the longest lag-phase, and viability was hampered in long-term
RAFT cultures (Figure 2). These two 3D culture methods were excluded from our single cell experiments,
due to their difficult handling and standardization of spheroid size. On the contrary, bead-based
systems offer a constant and calculated surface/volume ratio. Both 3D Cytodex3 and Nutrisphere
beads can be counted using standard methods, therefore the density of beads can be controlled for each
experiment. Cell cycle phase distribution showed moderate changes in only short-term cultures (day 4),
but not in long-term (day 9) with significant enrichment in the G2/M phase in 2D Coll, 3D Cytodex3 and
3D Nutrisphere cultures (Figure 3). Gene expression analysis by nanocapillary qRT-PCR (624 genes)
and 1536 well high-throughput qRT-PCR (62 genes) resulted in the selection of lung cancer markers
associated with higher (TMEM45A, SLC16A3, CD66, SLC2A1, CA9, CD24) or lower (EGFR) expression
in vivo or in 3D models compared to monolayer cultures (Table 2, Figures 4 and 5). Additionally,
TRA-1-60, pan-keratins, CD326, Galectin-3, CD274 with known clinical significance were also included
into the panel. Adenocarcinomas express keratins (K) such as: K8, K18, K19 and in some cases also
K7 and K20 as building blocks of intermediate filaments [46]. Interestingly, these cytokeratins also
localize to the cell surface of carcinoma cells to enhance adherence to ECM [47,48]. Therefore, an anti-
pan-keratin antibody (clone C11) was used for cell surface labeling which recognizes keratins 4, 5, 6, 8,
10, 13 and 18 [61].
The implemented multidimensional single cell proteome profiling revealed that 3D (Cytodex3
and Nutrisphere) cultures represent a transition from 2D to in vivo situation by intermediate marker
expression of TRA-1-60, TMEM45A, pan-keratin, CD326, MCT4, Gal-3, CD66, GLUT1, CD274. In 3D
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systems CA9, CD24, EGFR showed higher expression than in vivo (Figure 6). Our multi-parametric
single cell mass cytometry results delineated a map with different regions that represented 2D, 3D and
in vivo conditions with minimal overlap (Figure 7). Our single cell study was able to detect the rate
of heterogeneity in 2D, 3D cultures and in solid-tumor (Figures 6 and 7). As a result, the following
proteins were associated with advanced cancer: TRA-1-60 (9%), TMEM45A (37.5%), pan-keratin (50%),
CD326 (100%), MCT4 (50%), GAL-3 (30%), CD66 (100%), GLUT1 (100%) (Figure 8A).
The complexity of an organism is far from cell culture systems, but bead-based 3D cultures
provide a better representation of the in vivo conditions affording a more effective methodology for
different molecular biology studies, as well as for screening of compound libraries for novel anticancer
drug candidates.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/9/1093/s1,
File S1: Cancer Panel Assay List; File S2: qRT-PCR (1536) primer list; File S3: qRT-PCR data, Figure S4: HLA-A,B,C+
population of A549 cells.
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